The approval process for biosimilar erythropoiesis stimulating agents

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 9, 2014, Pages 1645-1651

  Wish, Jay B ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; LAW; PATENT; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; HEMATINICS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84923804295     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01770214     Document Type: Article

References (34)

1. Kozlowski S,Woodcock J,MidthunK, Sherman RB:Developing the nation’s biosimilars program. N Engl J Med 365: 385–388, 2011.
2. Section 2007 of the Affordable Care Act, Amending Section 351(i)(1) of the PHS Act, 804–821.
3. McCamish M, Woollett G: The state of the art in the development of biosimilars. Clin Pharmacol Ther 91: 405–417, 2012.
4. Weise M, Bielsky M-C, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK: Biosimilars: What clinicians should know. Blood 120: 5111–5117, 2012.
5. Federal Trade Commission: Emerging Health Care Issues: Follow- On Biologic Drug Competition, 2009. Available at: http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf. Accessed February 7, 2014.
6. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72: 322–328, 2013.
7. Blackstone EA, Fuhr JP Jr.: Innovation and competition: Will biosimilars succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 9: 24–27, 2012.
8. Simoens S: Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 3: 29–36, 2011.
9. Zuniga L, Calvo B: Biosimilars – the way forward. Hosp Pharm Europe 50: 33–34, 2010.
10. Mellstedt H: The future of biosimilars. Hosp Pharm Europe 49:33–34, 2010.
11. European Generic Medicines Association: Vision 2015. The EGA’s Thoughts on How to Improve the Legal and Regulatory Framework for Generic and Biosimilar Medicines, 2010. Available at: http://www.egagenerics.com/images/publication/PDF/EGA_Vision_2015.pdf. Accessed April 28, 2014.
12. Hackbarth GM, Crosson FJ, Miller ME: Report of the Congress: Improving Incentives in the Medicare Program,Washington,DC, Medicare Payment Advisory Commission, 2009.
13. US Department of Health and Human Services, Food and Drug Administration, Center forDrug Evaluation and Research, Center for Biologics Evaluation and Research: Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Draft Guidance, 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM291128.pdf. Accessed February 7, 2014.
14. FDA: Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license; correction—FDA. Proposed rule; correction. Fed Regist 63: 46718, 1998.
15. Wish JB, Chen K: The story of erythropoietin. In: Dialysis:History, Development and Promise, edited by Ing TS, Rahman MA, Kjellstrand CM, Singapore, World Scientific, 687–696, 2012.
16. World Health Organization: International Nonproprietary Names (INN) for Biological and Biotechnological Substances. World Health Organization, INN Working Document 05.179, 2006. Available at: http://www.who.int/medicines/services/inn/BioRevforweb.pdf. Accessed February 7, 2014.
17. Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N: The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 67: 2346–2353, 2005.
18. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S: Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 80: 88–92, 2011.
19. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU: A peptide-based erythropoietinreceptor agonist for pure red-cell aplasia. N Engl J Med 361: 1848–1855, 2009.
20. Jelkmann W: Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences. Am J Hematol 85: 771–780, 2010.
21. Seidl A, Hainzl O, Richter M, Fischer R, Bohm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I: Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 29: 1454–1467, 2012.
22. Mikhail A, Farouk M: Epoetin biosimilars in Europe: Five years on. Adv Ther 30: 28–40, 2013.
23. Brinks V, Hawe A, Basmeleh AHH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H: Quality of original and biosimilar epoetin products. Pharm Res 28: 386–393, 2011.
24. Sorgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M: Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: An open-label randomized controlled trial. BMC Clin Pharmacol 9: 10, 2009.
25. Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-Study Group: Therapeutic equivalence, long-termefficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72: 380–390, 2009.
26. Horl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo- PASS study group: Prospective multicenter study of HX575 (biosimilar epoetin-a) in patients with chronic kidney disease applying a target hemoglobin of 10–12 g/dl. Clin Nephrol 78: 24–32, 2012.
27. Lissy M, Ode M, Roth K: Comparison of the pharmacokinetic and pharmacodynamic profiles of oneUS-marketed and two Europeanmarketed epoetin alfas: Arandomized prospective study. DrugsRD 11: 61–75, 2011.
28. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R; Epoetin Zeta Study Group: Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin 24: 1407–1415, 2008.
29. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group: Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 24: 625–637, 2008.
30. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A: Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 25: 1215–1228, 2008.
31. Wiecek A, Ahmed I, Scigalla P, Koytchev R: Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther 27: 941–952, 2010.
32. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A; Epoetin Zeta Study Group: Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 27: 105–117, 2010.
33. Patient Protection and Affordable Care Act (PPACA): Title VII: Improving Access to Innovative Medical Therapies. Subtitle A: Biologic Price Competition and Innovation (BPCIA) Provisions of the Patient Protection and Affordable Care Act (PPACA)—Exclusivity Provisions. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed February 7, 2013.
34. Food and Drug Administration: ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in TheirManufacturing Process, 2003. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/2004d-0118-gdl0001.pdf. Accessed February 7, 2014.